Quoc Le-Nguyen
Chief Tech/Sci/R&D Officer at 89BIO, INC.
Net worth: 3 M $ as of 31/03/2024
Profile
Quoc Le-Nguyen is currently the Chief Technical Operations Officer & Head-Quality at 89bio, Inc. He previously worked as the Vice President-Manufacturing Operations at Bayer AG from 2007 to 2013 and as the SVP, Global Head-Technical Operations & Quality at Aduro BioTech, Inc. from 2015 to 2018.
Mr. Le-Nguyen completed his undergraduate degree at the University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
89BIO INC
0.24% | 17/02/2024 | 222,149 ( 0.24% ) | 3 M $ | 31/03/2024 |
Quoc Le-Nguyen active positions
| Companies | Position | Start |
|---|---|---|
| 89BIO, INC. | Chief Tech/Sci/R&D Officer | 01/03/2019 |
Former positions of Quoc Le-Nguyen
| Companies | Position | End |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2018 |
| BAYER AG | Corporate Officer/Principal | 01/09/2013 |
Training of Quoc Le-Nguyen
| University of California | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BAYER AG | Health Technology |
| 89BIO, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Quoc Le-Nguyen
